Press Coverage

Rare Poison Pill Strategy an Oddity Among Premium Price Takeover Bids Flurry

Excerpt: The 31.3% premium to Ramsay’s price over the last six months is reasonable for a change of control, said Brian Freitas, an analyst who publishes on research platform Smartkarma The share offer implies a forward earnings multiple of 33x versus an …

Barchart • (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now